New monoclonal antibody could be a game-changer in treating rare liver disease by reducing inflammation and fibrosis, says new study

PSC occurs in 1 out of 10,000 people, who are mostly male adults between 30 and 60 years old, and it commonly develops in ...

Monoclonal antibody shows promising results for rare liver disease

A multicenter study led by UC Davis Health has tested a new treatment designed to improve care for people with a rare liver ...

New monoclonal antibody safe and effective for rare liver disease

A new monoclonal antibody treatment has shown promising results for a rare liver disease called primary sclerosing ...
Medscape

First-in-Class Monoclonal Antibody Safe, Effective in Patients With Prurigo Nodularis, Study Finds

In a randomized clinical trial, vixarelimab demonstrates dose-dependent, long-term safety and efficacy in patients with ...

Mabwell Receives IND Clearance for Novel Anti-ST2 Monoclonal Antibody 9MW1911 to Initiate Phase IIa Study

Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that it has received IND clearance from the U.S. Food and Drug Administration (FDA ...

Invivyd Announces Initiation of DECLARATION Clinical Trial, a Phase 3 Placebo-Controlled Pivotal Study of VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

DECLARATION is a Phase 3, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of VYD2311 in the prevention of COVID ...

Invivyd Earns Fast Track Designation for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

NEW HAVEN, Conn., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for VYD2311, an ...